

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – March 12, 2014 @ 4:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. February 12, 2014 DUR Minutes – Vote
- B. February 12, 2014 DUR Recommendation Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on DUR / Medication Coverage Authorization Unit / FDA Safety Alerts – See Appendix B

- A. Medication Coverage Activity for February 2014
- B. Pharmacy Help Desk Activity for February 2014
- C. Updates on FDA Safety Alerts

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Adempas[®] (Riociguat) and Opsumit[®] (Macitentan) – See Appendix C

- A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Select Cephalosporins – See Appendix D

- A. Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

7. Annual Review of Erythropoiesis Stimulating Agents – See Appendix E

- A. Introduction
- B. Utilization of Erythropoiesis Stimulating Agents
- C. Prior Authorization Review
- D. Market News and Updates
- E. Discussion
- F. Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. Annual Review of Insomnia Medications – See Appendix F

- A. Current Authorization Criteria
- B. Utilization of Insomnia Medications
- C. Prior Authorization Review
- D. Market News and Updates
- E. COP Recommendations
- F. Utilization Details

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

9. Annual Review of Oral Antihistamines – Appendix G

- A. Current Authorization Criteria
- B. Utilization of Oral Antihistamines
- C. Prior Authorization Review
- D. Market News and Updates
- E. COP Recommendations
- F. Utilization Details

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. Annual Review of Smoking Cessation Products – Appendix H

- A. Current Authorization Criteria
- B. Utilization Review
- C. Prior Authorization Review
- D. Market News and Updates
- E. Discussion
- F. COP Recommendations
- G. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

11. Annual Review of Benzodiazepine Medications – See Appendix I

- A. Current Authorization Criteria
- B. Utilization of Benzodiazepines
- C. Prior Authorization Review
- D. Market News and Updates
- E. COP Recommendations
- F. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

12. 60 Day Notice to Prior Authorize Ophthalmic Anti-Inflammatory Medications – See Appendix J

- A. Introduction
- B. Economic Impact
- C. Market Analysis
- D. COP Recommendations

Items to be presented by Nico Gomez, Executive Chief, Dr. Muchmore, Chairman:

13. Updates Regarding OHCA

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

14. FDA and DEA Updates – See Appendix K

15. Future Business

A. Annual Reviews

B. New Product Reviews

16. Adjournment